Video

VIDEO: Direct-to-patient study empowers patients, accelerates research


 

AT THE 2016 ASCO ANNUAL MEETING

CHICAGO – The Metastatic Breast Cancer Project is an innovative direct-to-patient initiative that allows metastatic breast cancer patients from around the country – often found through social media – to enroll themselves into a research study, primary investigator Dr. Nikhil Wagle said at the annual meeting of the American Society of Clinical Oncology.

Patients interested in participating can visit the project’s website and consent themselves into the study. Patients then fill out a questionnaire about their cancer and their treatments and provide a saliva sample using an at-home kit. Meanwhile, researchers obtain medical records and collect portions of stored tumor samples if available. The overarching goal of the project is to expedite metastatic breast cancer (MBC) genomics research by gaining access to a larger pool of patients with MBC and to generate novel research questions. Over 1,100 patients have already enrolled in the study, and many of them fall into groups of patients – such as those with extraordinary response to treatment or those of racial/ethnic minorities – that are normally challenging to capture in traditional studies.

In a video interview, Dr. Wagle of the Dana-Farber Cancer Institute in Boston and the Broad Institute in Cambridge, Mass., summarizes the unique benefits of the project and discusses future plans, which include gathering patient genomic data from blood biopsy samples and expanding the project to other types of cancers.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

jcraig@frontlinemedcom.com

Recommended Reading

Effects of exercise interventions during different treatments in breast cancer
MDedge Hematology and Oncology
Omission of dexamethasone from antiemetic treatment for highly emetogenic chemotherapy in breast cancer patients with hepatitis B infection or diabetes mellitus
MDedge Hematology and Oncology
Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy
MDedge Hematology and Oncology
Investigational CDK4/6 inhibitor shows activity, less toxicity
MDedge Hematology and Oncology
Targeting vagal activity could improve breast cancer survival
MDedge Hematology and Oncology
Biosimilar trastuzumab comparable on safety, efficacy
MDedge Hematology and Oncology
VIDEO: Dr. Rugo discusses regulatory future for trastuzumab biosimilar
MDedge Hematology and Oncology
MONARCH 1: Abemaciclib is active in refractory HR+, HER2– breast cancer
MDedge Hematology and Oncology
VIDEO: Doctors should be challenged to extend AIs
MDedge Hematology and Oncology
Ethnic groups differ in BRCA risk management
MDedge Hematology and Oncology